RxDoctor Payments DataLook up a doctor →

Stephen Weinroth, MD

Infectious Disease · Fairfax, VANPI 1033130430

Payments from drug & device makers

$157,140in general payments, 2019–2025

Across 767 payments — averaging $204.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Melinta Therapeutics, LLC$68K
  • Gilead$44K
  • Theratechnologies Inc.$34K
  • Viiv Healthcare Company$5K
  • Merck$958
  • Insmed, Inc.$677
  • plus $4K from 21 others

What the payments were for

  • Consulting fees$5,5104%
  • Speaking & faculty fees$113,82672%
  • Travel & lodging$21,50014%
  • Food & beverage$15,76310%
  • Education$5410%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$157,140 in reported general payments places this provider in the 90th percentile of 194 infectious disease providers in Virginia.

See all infectious disease providers in Virginia

Medicare billing

Part B allowed, 2024
$280,417
Medicare patients
263
Services billed
78,162

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrogarzoIbalizumab-Uiyk20$231,787
BiktarvyBictegrav/Emtricit/Tenofov Ala52$213,977
DovatoDolutegravir Sodium/Lamivudine56$167,098
ErtapenemErtapenem Sodium17$6,890
Methenamine Hippurate29$2,445
Meropenem12$1,440
Disulfiram13$1,344
ValacyclovirValacyclovir Hcl18$770
Doxycycline Hyclate19$588
CefuroximeCefuroxime Axetil27$221
Ciprofloxacin Hcl23$169
Levofloxacin13$42
Atorvastatin Calcium11$26

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Theratechnologies Inc.Trogarzo$34,106$231,78720 claims
GileadBiktarvy$44,381$213,97752 claims
Viiv Healthcare CompanyDovato$5,018$167,09856 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 194 infectious disease providers in Virginia.

Other infectious disease in Fairfax

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →